
Stig Wergeland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6054409/publications.pdf Version: 2024-02-01



STIC WERCELAND

#	Article	lF	CITATIONS
1	Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e422.	6.0	107
2	Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model. PLoS ONE, 2011, 6, e26262.	2.5	74
3	Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1833-1840.	3.0	57
4	Body mass index influence interferon-beta treatment response in multiple sclerosis. Journal of Neuroimmunology, 2015, 288, 92-97.	2.3	56
5	Deep Gray Matter Demyelination Detected by Magnetization Transfer Ratio in the Cuprizone Model. PLoS ONE, 2013, 8, e84162.	2.5	48
6	Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 19-22.	1.9	39
7	The cuprizone model: regional heterogeneity of pathology. Apmis, 2012, 120, 648-657.	2.0	36
8	Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International, 2015, 83-84, 28-40.	3.8	28
9	Increasing serum levels of vitamin A, D and E are associated with alterations of different inflammation markers in patients with multiple sclerosis. Journal of Neuroimmunology, 2014, 271, 60-65.	2.3	25
10	Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology, 2015, 285, 180-186.	2.3	22
11	No association of tobacco use and disease activity in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e260.	6.0	21
12	Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 2015, 280, 21-28.	2.3	19
13	Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. Journal of Neuroimmunology, 2020, 339, 577091.	2.3	18
14	Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. Scientific Reports, 2021, 11, 7174.	3.3	17
15	α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. Multiple Sclerosis Journal, 2019, 25, 987-993.	3.0	16
16	Perinatal Depression and Anxiety in Women With Multiple Sclerosis. Neurology, 2021, 96, e2789-e2800.	1.1	14
17	1,25-Dihydroxyvitamin-D3 induces brain proteomic changes in cuprizone mice during remyelination involving calcium proteins. Neurochemistry International, 2018, 112, 267-277.	3.8	13
18	Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis. Journal of Neuroimmunology, 2018, 323, 73-77.	2.3	13

STIG WERGELAND

#	Article	IF	CITATIONS
19	Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 50, 102801.	2.0	13
20	Effects of vitamin D on axonal damage during de- and remyelination in the cuprizone model. Journal of Neuroimmunology, 2018, 321, 61-65.	2.3	12
21	Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732097304.	1.0	10
22	The Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune Encephalomyelitis. Journal of Proteomics and Bioinformatics, 2016, 9, 209-219.	0.4	9
23	Treatment-resistant immune thrombocytopenic purpura associated with LDN use in a patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e25.	6.0	6
24	Association of adverse childhood experiences with the development of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 645-650.	1.9	4
25	A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. PLoS ONE, 2021, 16, e0256155.	2.5	2
26	Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110220.	1.0	1
27	Abuse and revictimization in adulthood in multiple sclerosis: a cross-sectional study during pregnancy. Journal of Neurology, 2022, 269, 5901-5909.	3.6	1